Literature DB >> 29693191

miR‑186 functions as a tumor suppressor in osteosarcoma cells by suppressing the malignant phenotype and aerobic glycolysis.

Qianren Xiao1, Zhihui Wei1, Yunyun Li2, Xin Zhou1, Jiajun Chen1, Tengyu Wang1, Gaohai Shao1, Minghua Zhang1, Zhongzu Zhang1.   

Abstract

Osteosarcoma (OS) is the most common primary bone malignancy among children and adolescents. Deregulation of microRNAs has been well documented in OS, while the putative effects of miR‑186 have not been identified yet. In the present study, we assessed the expression of miR‑186 in a cohort of 40 OS tissues and explored its effects on OS cells. As expected, miR‑186 was suppressed in OS tissues compared with relative normal tissues. Overexpression of miR‑186 inhibited cell proliferation, arrested the cell cycle progression and suppressed the cell invasion of the HOS and U2 OS cell lines. These results indicated the tumor‑suppressive role of miR‑186 in OS. Among the target genes of miR‑186, we found that pituitary tumor transforming gene 1 (PTTG1) may be a target gene of miR‑186 in OS and that the overexpression of PTTG1 could partially abolish miR‑186‑mediated suppressive effects on OS cells. Aerobic glycolysis is the major way of energy supply and is one of the characteristic phenotypes of tumor cells. In addition, we found that overexpression of miR‑186 significantly suppressed the expression of hypoxia‑inducible factor 1 (HIF‑1) and inhibited the glucose uptake and lactate production of OS cells. Collectively, our findings demonstrated that miR‑186 functions as a tumor suppressor in OS cells partially by targeting PTTG1 and that HIF‑1‑mediated suppression of aerobic glycolysis may be also involved in its suppressive effects.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29693191     DOI: 10.3892/or.2018.6394

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A.

Authors:  Jianhua Lu; Weikai Chen; Hao Liu; Huilin Yang; Tao Liu
Journal:  J Clin Lab Anal       Date:  2019-07-31       Impact factor: 2.352

Review 3.  Lactate in Sarcoma Microenvironment: Much More than just a Waste Product.

Authors:  Maria Letizia Taddei; Laura Pietrovito; Angela Leo; Paola Chiarugi
Journal:  Cells       Date:  2020-02-24       Impact factor: 6.600

4.  ROCK2 Promotes Osteosarcoma Growth and Glycolysis by Up-Regulating HKII via Phospho-PI3K/AKT Signalling.

Authors:  Binbin Deng; Jianyong Deng; Xuan Yi; Yeqing Zou; Chen Li
Journal:  Cancer Manag Res       Date:  2021-01-18       Impact factor: 3.989

5.  Targeting Nuclear NAD+ Synthesis Inhibits DNA Repair, Impairs Metabolic Adaptation and Increases Chemosensitivity of U-2OS Osteosarcoma Cells.

Authors:  Alexandra Kiss; Arnold Péter Ráduly; Zsolt Regdon; Zsuzsanna Polgár; Szabolcs Tarapcsák; Isotta Sturniolo; Tarek El-Hamoly; László Virág; Csaba Hegedűs
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

6.  Circular RNA CDR1as sponges miR-7-5p to enhance E2F3 stability and promote the growth of nasopharyngeal carcinoma.

Authors:  Qiong Zhong; Juncong Huang; Jiawang Wei; Renrui Wu
Journal:  Cancer Cell Int       Date:  2019-10-01       Impact factor: 5.722

7.  BAG2 Promotes Proliferation and Metastasis of Gastric Cancer via ERK1/2 Signaling and Partially Regulated by miR186.

Authors:  Lisha Sun; Guanglei Chen; Anqi Sun; Zheng Wang; Haibo Huang; Ziming Gao; Weitian Liang; Caigang Liu; Kai Li
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

8.  MicroRNA-186 improves fracture healing through activating the bone morphogenetic protein signalling pathway by inhibiting SMAD6 in a mouse model of femoral fracture: An animal study.

Authors:  C Wang; G-F Zheng; X-F Xu
Journal:  Bone Joint Res       Date:  2019-12-03       Impact factor: 5.853

9.  Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients.

Authors:  Chung-Che Wu; Titus Ime Ekanem; Nam Nhut Phan; Do Thi Thuy Loan; Sz-Ying Hou; Kuen-Haur Lee; Chih-Yang Wang
Journal:  Int J Med Sci       Date:  2020-10-22       Impact factor: 3.738

Review 10.  Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Wen-Hong Wang; Xian-Ning Dong; Li-Mei-Li Tian
Journal:  World J Gastroenterol       Date:  2020-08-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.